A
Revolutionary
Diagnostic
Tool
A
Revolutionary
Diagnostic
Tool
Spermosens AB is developing a revolutionary platform technology for diagnosing male-factor infertility and directing to the right infertility treatment.
It has not been possible to predict if the sperms can actually fertilize the oocyte (egg cell). The diagnostics have relied on sperms’ physical properties and motility, thus directing the majority of treatments to the highly invasive and unnecessary ICSI, instead of the safer and more natural standard-IVF.
Male Infertility
15% of the couples are globally affected by infertility, with male-factor accounting for 50% of the global infertility.
Unfortunately, there has been little progress in methods to diagnose male-factor infertility, and 40% of these cases remain unexplained.
Spermosens aims to empower caregivers and patients alike, helping to understand the cause of male-factor infertility despite seemingly normal sperms.
15%
GLOBAL INFERTILITY
50% MALE
50%
DECREASE IN SPERM COUNT SINCE 1970S
40%
UNEXPLAINED MALE INFERTILITY
2.4M
IVF CYCLES PERFORMED ANNUALLY
20%
SUCCESS RATES
The Answer
Spermosens’ patent-pending technology is based on the 2014 discovery of the JUNO protein, and has emanated in a user friendly and small footprint diagnostic system which in 30 minutes predicts the fusion capacity of the sperms.
Breakthrough Platform technology
This will lead to an immediate decision if the sperm sample is suitable for standard-IVF or ICSI, thus drastically limiting the number of cycles required for fertilisation and reducing the burden of infertility on the female partner.
Millions of couples waiting in queue for 1-3 years for IVF can now be helped quicker and more economically.
SIGN UP AND STAY CONNECTED
Get the latest news by signing up to our monthly newsletter. We welcome you to contact us with any thoughts you may have.
John Lempert
CEO
